Fresenius Medical Care AG & Co. KGaA reported that net income for the third quarter of 2015 fell 3% to $262 million, compared to $271 million for the third quarter of 2014.

Revenue in North America grew 11% in the third quarter of to $3,013 million. Organic revenue growth was 6%. Net health care revenue grew 12% to $2,794 million with a same market treatment growth of 5%. Net Dialysis Care revenue increased 6% to $2,314 million and Care Coordination revenue increased 56% to $480 million (organic growth of 17%). Dialysis product revenue increased 3% to $219 million.

Net revenue for the third quarter of 2015 increased 3% to $4,231 million (+9% at constant currency), compared to the third quarter of 2014. Organic revenue growth worldwide was 6%. Net Health Care revenue grew 6% to $3,402 million (+10% at constant currency). Dialysis product revenue was down 9% to $829 million, which Fresenius attributes to a negative currency impact in the three international segments. On a constant currency basis, the dialysis product revenue increased 2%.

International revenue decreased 12% to $1,213 million (an increase of 5% on a constant currency basis). Organic revenue growth was 6%. Net health care revenue decreased 13% to $608 million (+6% at constant currency). Dialysis product revenue decreased 12% to $605 million (+3% at constant currency).